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Objectives This study sought to evaluate the outcome and prevalence of viral endomyocardial infection after cardiac transplantation.
Background Viral myocardial infection causes heart failure, but its role after cardiac transplantation is unclear. We hypothe-
sized that viral infection of the cardiac allograft reduces graft survival.
Methods Between June 1999 and November 2004, 94 pediatric cardiac transplant patients were screened for the pres-
ence of viral genome in serial endomyocardial biopsies (EMBs) using polymerase chain reaction (PCR) assays.
Graft loss, advanced transplant coronary artery disease (TCAD), and acute rejection (AR) were compared in the
PCR-positive (n  37) and PCR-negative (n  57) groups, using time-dependent Kaplan-Meier and Cox regres-
sion analyses. From November 2002 to November 2004, intravenous immunoglobulin therapy (IVIG) was admin-
istered to patients with PCR-positive EMBs. The outcomes of the IVIG-treated, PCR-positive patients (n  20)
were compared with IVIG-untreated, PCR-positive patients (n  17).
Results Viral genomes were detected in EMBs from 37 (39%) patients; parvovirus B19, adenovirus, and Epstein-Barr vi-
rus (EBV) were the most common. The PCR-positive group (n  37, 25% graft loss at 2.4 years) had decreased
graft survival (p  0.001) compared with the PCR-negative group (n  57, 25% graft loss at 8.7 years) and de-
veloped advanced TCAD prematurely (p  0.001). The number of AR episodes was similar in both groups. On
multivariate analysis, presence of viral genome was an independent risk factor for graft loss (relative risk: 4.2,
p  0.015). The time to advanced TCAD after becoming PCR-positive was longer in the IVIG-treated patients
(p  0.03) with a trend toward improved graft survival (p  0.06).
Conclusions Viral endomyocardial infection is an independent predictor of graft loss in pediatric cardiac transplant recipients.
This effect appears to be mediated through premature development of advanced TCAD. IVIG therapy in this sub-
group may improve survival and merits further investigation. (J Am Coll Cardiol 2010;56:582–92) © 2010 by
the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.060d
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hver the last 2 decades, the prevalence of heart failure has
ignificantly increased in the developed world (1). Simulta-
eously, cardiac allograft transplantation has become the
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August 10, 2010:582–92 Viral Infection and Graft Loss in Pediatric Cardiac Transplantationardiac graft loss have been identified (2,3), the majority of
hich are not amenable to modification. Viral allograft
nfection is a potential risk factor amenable to therapy
nd deserves further evaluation.
Viral myocarditis of the native heart is an established
tiology for dilated cardiomyopathy (4,5). We have hypoth-
sized that viral infection of the post-transplant heart is also
etrimental. The histologic diagnostic criteria for myocar-
itis, the Dallas criteria, rely heavily on the combination of
nflammatory infiltrate, myocyte necrosis, edema, and fibro-
is (6). Cardiac transplant rejection, as defined by the
nternational Society of Heart and Lung Transplantation
7), appears similar to the criteria for myocarditis. It is
ossible, therefore, to speculate that the 2 disorders are
elated, both triggered by viral infection. Viral genome has
een detected in the cardiac allograft after transplantation
8–11) and is associated with an increased risk for rejection
nd graft loss (8,11). A similar association has also been
hown in lung and renal transplant recipients (12,13).
Viral infections, especially cytomegalovirus (CMV), have
een implicated in the pathogenesis of coronary atheroscle-
osis in the general population and transplant coronary
rtery disease in cardiac transplant patients (14–16). Treat-
ent with ganciclovir and anti-CMV immunoglobulin
ecreases the risk of transplant coronary artery disease
TCAD) in cardiac transplant recipients with systemic
MV infection (17,18). Intravenous immunoglobulin
IVIG) therapy for acute viral myocarditis is common in
any centers, based on studies suggesting a beneficial role
f IVIG in these patients (19,20). In addition, IVIG has
een utilized for its immunomodulatory effects in transplant
ecipients with viral infection as well as other conditions
ith possible immune-mediated, infectious agent–triggered
tiologies (21,22).
In this study, we compared the outcomes of cardiac
ransplant patients with viral polymerase chain reaction
PCR)-positive versus -negative endomyocardial biopsies
EMBs), as well as the outcomes of IVIG-treated PCR-
ositive patients with that of PCR-positive, IVIG-
ntreated counterparts.
ethods
atient cohort. All consecutive cardiac transplant patients
ollowed in Texas Children’s Hospital between June 1,
999, and November 30, 2004, were eligible for selection.
ive patients who had undergone cardiac transplantation in
nother institution and 2 patients who did not undergo any
MBs due to lack of vascular access or clinical instability
ere excluded. The final study cohort consisted of 94
atients. Seven patients transferred care to another institu-
ion prior to completion of the study and were censored
fter the last day of patient encounter.
Baseline recipient and donor characteristics, immunosup-
ressive regimen, and post-transplant patient course data were
etrospectively collected from hospital records. The study cohort was divided into 2 exposure
roups, based on the presence or
bsence of viral genome in their
MBs. An overview of the study
esign and analysis is given in
igure 1.
MB, histopathology, and PCR.
erial surveillance right ventricu-
ar EMBs were performed as per
n established schedule (Online
able 1). Patients with concern
or acute graft dysfunction also
nderwent nonscheduled EMBs.
istological grading of biopsy
pecimens was performed ac-
ording to Texas Heart Institute
nd International Society of Heart
nd Lung Transplantation crite-
ia (7,23). PCR analysis of all EMBs for the presence of
denovirus, parvovirus B19, Epstein-Barr virus (EBV),
MV, and enteroviral genomes was performed by individ-
als who were blinded to the clinical course, as previously
escribed (11). Detection of viral genome in EMBs was
onsidered diagnostic of viral endomyocardial infection
current or past) for purposes of this study.
utcomes. The patient cohort was followed for the out-
omes of all-cause graft loss, advanced TCAD, and acute
ejection (AR) until June 30, 2005. All patients underwent
aseline coronary angiograms 3 months after transplanta-
ion followed by annual screening coronary angiograms,
tarting from 1 year after transplantation. TCAD was
iagnosed on the basis of either the coronary angiograms or
he histological evaluation of the cardiac allograft in patients
ho suffered graft loss. Severity of TCAD was graded as
efined by Cardiac Transplant Research Database (CTRD)
riteria (Online Table 2) (24) and classified as advanced
CAD if criteria for moderate or severe TCAD were met.
R was diagnosed by the treating physicians in conjunction
ith the cardiac pathologist on the basis of the clinical
icture and histopathology results of EMBs. All rejection
pisodes were treated by pulse steroid therapy plus a change
n short- and/or long-term immunosuppressive therapy.
VIG treatment. From November 2002 to November
004, the management of viral endomyocardial infection in
ardiac transplant patients at our institution included ad-
inistration of a single dose of 1 g/kg IVIG, given after
ach PCR-positive biopsy, either during the same hospital
isit or on a follow-up visit. All patients with any virus-
ositive EMBs were eligible to receive IVIG. This treat-
ent protocol was discontinued after November 2004 due
o an institutional restriction on off-label use of IVIG,
riggered in part by a shortage of IVIG supplies nationally.
s a subgroup analysis, outcome data from the viral PCR-
ositive IVIG-treated patients were compared with their
VIG-untreated viral PCR-positive counterparts (historic or
Abbreviations
and Acronyms
AR  acute rejection
CMV  cytomegalovirus
EBV  Epstein-Barr virus
EMB  endomyocardial
biopsy
ISHLT  International
Society of Heart and Lung
Transplantation
IVIG  intravenous
immunoglobulin
PCR  polymerase chain
reaction
TCAD  transplant
coronary artery diseaseoncurrent) as controls.
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Viral Infection and Graft Loss in Pediatric Cardiac Transplantation August 10, 2010:582–92tatistical analysis. Univariate analysis for freedom from
n event was performed using Kaplan-Meier analysis and
og-rank test, and multivariate analysis using Cox propor-
ional hazards regression. Viral endomyocardial infection
as treated as a time-dependent binary covariate for survival
nalyses. AR episodes were compared using Mann-Whitney
est and Poisson regression. Covariates between the 2
roups were compared using t test, chi-square, or Fisher
xact tests. A p value of 0.05 was considered significant.
atients who had transferred care to another institution
rior to completion of the study were considered lost to
ollow-up and were censored as “alive” on the last day of
Figure 1 Overview of Study Design With Patient Selection,
Follow-Up, and Analysis
IVIG  intravenous immunoglobulin; PCR  polymerase chain reaction;
TCAD  transplant coronary artery disease.heir follow-up in the survival analysis. Analysis was done sith Stata version 8.2 software (Stata Corp., College Station,
exas).
esults
atient cohort and baseline characteristics. The study
ohort (n  94) had 39 females (41.5%) and 55 (58.5%)
ales, with a mean age of 6.5  5.5 years (range 0.06 to
8.3 years) at the time of transplantation. The mean
ollow-up period from the time of transplantation to the
ompletion of the study was 4.5 years (range 0.16 to 16.22
ears) for a total of 420 patient-years. Congenital heart
isease (34 of 94, 36%) was the most common indication for
ardiac transplantation, followed by dilated cardiomyopathy
33 of 94, 35%), restrictive cardiomyopathy (13 of 94, 14%),
nd cardiac retransplantation (12 of 94, 13%). All children
ere initially treated with a standard triple-drug immuno-
uppressive regimen consisting of cyclosporine or tacroli-
us, prednisone, and azathioprine or mycophenolate
ofetil. No induction therapy was used. The antiprolifera-
ive agent (azathioprine or mycophenolate) was discontin-
ed in 41% of the patients at an average of 1.5 years after
ransplantation, due to persistent leukopenia. The patients
ere then maintained on dual therapy with steroids and
alcineurin inhibitors. The baseline characteristics of the
iral PCR-positive and -negative groups are shown in Table 1.
ifferences between the 2 groups included; the PCR-
ositive group had a higher mean recipient age (p  0.007)
nd weight (p  0.002) at transplant, higher mean donor
ge (p 0.004), higher number of retransplants (p 0.02),
ore patients with viral genome detected in the explanted
eart (p  0.03), and more patients on left ventricular assist
evice/extracorporeal membrane oxygenation at transplant
p  0.05). There was no difference in the pattern of im-
unosuppression between the PCR-positive and -negative
roups. The PCR-positive and -negative groups were sim-
lar with respect to the initial triple-drug therapy combina-
ion. There was no statistically significant difference in the 2
roups with respect to the percentage of patients in whom
zathioprine or mycophenolate was discontinued and im-
unosuppression transitioned to a combination of pred-
isone and a calcineurin inhibitor alone. No adjustments in
mmunosuppression were made if virus was detected in the
yocardium.
Of the 94 patients in the study cohort, 24 underwent
ransplantation before the onset of the study in June
999. Of these, 19 remained PCR-negative and 5 became
CR-positive during the course of the study. At their
ntry into the study, the mean time from transplantation
as 5.19 years in the 19 PCR-negative patients and 3.84
ears in the 5 PCR-positive patients. The average
ollow-up period after transplantation was 4.99 years in
he PCR-negative patients and 3.64 years in the PCR-
ositive patients.
iral PCR results of EMBs. PCR was performed on 928erial EMBs from the 94 study patients. Viral genome was
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August 10, 2010:582–92 Viral Infection and Graft Loss in Pediatric Cardiac Transplantationmplified from the myocardium of 39% (37 of 94) patients
nd 8.9% (83 of 928) of the biopsies. Parvovirus B19
enome was amplified most commonly and was found in
1.1% of all positive biopsies, from 24.5% (23 of 94)
atients (62.1% of PCR-positive patients). Adenoviral ge-
ome was detected in 9 (9.6%) patients (24.3% of PCR-
ositive patients), EBV in 8 (8.5%) patients (21.6% of
CR-positive patients), CMV in 4 (4.3%) patients, and
nterovirus in 1 (1%) patient (Fig. 2A). Eight patients
8.5%) had more than 1 virus type amplified, either in the
ame (3 cases) or follow-up EMB (5 cases). Viral genome
ersisted for 6 months in 40% (15 of 37) of the virus-
ositive patients; 14 of these patients were parvovirus
19–positive and 1 was EBV-positive. Majority of patients
ith parvovirus-positive EMBs showed evidence of chronic
ersistence of viral genome, with 61% (14 of 23) positive for
arvovirus 6 months after the initial detection, and in the
ubgroup where a follow-up EMB was available more than
year after the initial parvovirus-positive EMB, 88% (14 of
6) showed persistence or recurrence of parvoviral genome
1 year after the initial detection. A change in the infecting
irus was noted over the study period (Fig. 2B) with
ncreasing incidence of parvovirus B19 from 0% of the
iopsies in 1999 to 18% in 2004 (p  0.001, Fisher exact)
nd decreasing incidence of adenovirus from 7.5% of the
iopsies in 1999 to 0% in 2004 (p  0.001, Fisher exact).
ost of the viral endomyocardial infections were clinically
ilent and detected on routine surveillance biopsies. Only 1
atient with parvovirus-positive biopsy developed aplastic
nemia in our patient cohort.
isk for viral endomyocardial infection. Patients were
ost prone to develop viral endomyocardial infection in the
rst year after cardiac transplantation; 59% (22 of 37) of the
iral PCR-positive patients had their first viral PCR-
ositive EMB within the first year after transplantation. To
et a more accurate estimation of how the time period from
ransplantation affected the risk for viral endomyocardial
nfection, we performed a Kaplan-Meier analysis of
reedom from viral endomyocardial infection after trans-
lantation on the 70 patients (transplanted after June 1,
999) on whom viral PCR status of all the EMBs
erformed after transplantation was known. The cumu-
ative probability of developing viral endomyocardial
nfection was 35% (95% confidence interval [CI]: 26% to
8%) by the end of the first year after transplantation and
3% (95% CI: 48% to 78%) by the end of the fifth year
fter transplantation (Fig. 2C).
ong-term graft survival. Graft survival was decreased
p  0.001, log-rank) in the PCR-positive group compared
ith the PCR-negative group. The risk for graft loss in the
CR-positive group was 4.2 (p  0.015, 95% CI: 1.33 to
3.29) times that of the PCR-negative group, after adjust-
ng for recipient age, recipient weight, recipient sex, donor
ge, retransplantation, and AR episodes, using Cox regres-
ion analysis. The median graft survival was 4.8 years in the
CR-positive group (Fig. 2D) compared with 12.4 years in 8he whole cohort. The median graft survival time in the
CR-negative patients could not be estimated due to lack of
nough graft failures during the study period. Eleven (35.5%)
f the PCR-positive patients and 11 (19.3%) of the PCR-
egative patients lost their grafts (death or retransplantation)
uring the study period. The causes of graft loss are listed in
nline Table 3. After excluding patients with nonallograft-
pecific causes of mortality (malignancy, aplastic anemia, and
ulmonary vein stenosis), the PCR-positive group still had a
igher risk for premature graft loss (p  0.01, log-rank).
ersistence of viral genome in EMBs for longer than 6 months
id not further increase the risk of graft loss. Risk factors
valuated for and predictive of graft loss are listed in Online
ables 4 and 5, respectively.
dvanced TCAD. Data on coronary arteries were not
vailable in 7 of the 94 study patients, as they were within
he first year after transplantation and had not undergone
he first annual screening coronary angiography by the end
f the current study. Of the remaining 87 patients on whom
oronary angiography or coronary histopathology results
ere available, 33 (38%) patients were PCR-positive and 54
62%) patients were PCR-negative. One patient developed
dvanced TCAD before detection of viral endomyocardial
nfection and was considered as PCR-negative for purposes
f this analysis. Average follow-up time after transplanta-
ion was 5.15 years in the PCR-negative patients compared
ith 3.87 years in the PCR-positive patients. Fourteen
atients (16%) developed advanced TCAD: 7 (21.2%) of
he PCR-positive and 7 (12.9%) of the PCR-negative
atients. PCR-positive patients developed advanced TCAD
rematurely compared with the PCR-negative group (p 
.001, log-rank) and had an 8.3 times higher risk for
eveloping advanced TCAD (p  0.001, 95% CI: 2.48 to
8.02) (Fig. 2E). After adjusting for time from transplan-
ation at entry into the study, being PCR-positive remained
risk factor for premature development of advanced TCAD
p  0.002, log-rank). The risk for developing premature
dvanced TCAD in the PCR-positive group was 6.8 (p 
.01, 95% CI: 1.47 to 32.06) times that of the PCR-
egative group, after adjusting for recipient weight, age, and
ex, donor age, retransplantation, time from transplantation,
nd AR episodes, using Cox regression analysis. Persistence
f viral genome in EMBs for longer than 6 months did not
urther add to the risk of developing advanced TCAD. The
edian time to developing advanced TCAD was 4.8 years
n the PCR-positive group compared with 12.2 years in the
hole cohort. The median time to developing advanced
CAD in the PCR-negative group could not be calculated
ue to insufficient number of events during the study period.
cute graft rejection. A total of 101 rejection episodes
ccurred in 62 of the 94 patients during the study period.
o statistically significant association was found between
iral endomyocardial infection and AR. Concomitant rejec-
ion was present in 8.3% of the PCR-positive biopsies and
.6% of the PCR-negative biopsies.
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Viral Infection and Graft Loss in Pediatric Cardiac Transplantation August 10, 2010:582–92Baseline Demographics and Covariates in the PCR-Positive and -Negative GroupsTable 1 Baseline Demographics and Covariates in the PCR-Positive and -Negative Groups
Characteristic PCR-Positive Group PCR-Negative Group p Value
Patients 37 57
Recipient sex NS
Male 20 (54%) 35 (61.4%)
Female 17 (46%) 22 (38.6%)
Recipient ethnic group 34/37 52/57 NS
White 13 (38.2%) 23 (44.2%)
Black 5 (14.7%) 10 (19.2%)
Hispanic 15 (44.1%) 18 (34.6%)
Asian 1 (2.9%) 1 (1.9%)
Others 0 (0%) 0 (0%)
Recipient age 37/37 57/57 0.01
Mean  SD 7.9 5.64 5.1 5.03
Median 7.5 3.0
Range 0.1–18.3 0.06–17.6
Recipient age category, yrs NS
1 4 (10.8%) 10 (17.5%)
1 33 (89.2%) 30 (82.5%)
Recipient weight, kg 28.3 3.28 17.1 1.74 0.002
Indication for transplantation NS
CHD 16 (35.6%) 18 (36.7%)
DCM 14 (31.1%) 20 (40.8%)
RCM 4 (8.9%) 9 (18.4%)
Retransplant 9 (20.0%) 2 (4.1%)
Other 2 (4.4%) 0 (0%)
UNOS waiting-list status NS
1 30 (68.2%) 31 (63.3%)
2 14 (31.8%) 18 (36.7%)
Wait time, days (mean) 132 153 NS
Ventilator dependence pre-transplantation 12 (29.3%) 11 (26.8%) NS
LVAD/ECMO dependence pre-transplantation 6 (13.9%) 1 (2.4%) 0.05
Ionotrope dependence pre-transplantation 27 (65.9%) 21 (51.2%) NS
Hospitalization pre-transplantation NS
ICU 18 (41.7%) 14 (33.3%)
Non-ICU 10 (23.3%) 8 (19.1%)
Catheterization
PSP, mm Hg (mean) 29.0 30.0 NS
PCWP, mm Hg (mean) 13.6 15.2 NS
PVR, Woods Units (mean) 3.2 2.7 NS
CMV status seropositivity
Recipient 17 (42.5%) 17 (39.5%) NS
Explant myocarditis 10 (29.4%) 10 (21.3%) NS
Viral PCR-positive explant 8 (26.7%) 2 (6.1%) 0.03
Donors
Donor cold ischemia time, min (mean) 246 230 NS
Donor sex NS
Male 22 (57.9%) 23 (59%)
Female 16 (42.1%) 16 (41%)
Donor ethnicity NS
White 22 (61.1%) 18 (50.0%)
Black 5 (13.9%) 10 (27.8%)
Hispanic 8 (22.2%) 8 (22.2%)
Asian 1 (2.8%) 0 (0.0%)
Other 0 (0.0%) 0 (0.0%)
Donor age, yrs 0.004
Mean  SD 9.0 6.60 5.2 5.13
Median 8.5 3.0
Range 0.33–23 0.06–19Continued on next page
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August 10, 2010:582–92 Viral Infection and Graft Loss in Pediatric Cardiac Transplantationirus subtype and outcome. After adjusting for viral
ubtypes using Cox regression, adenoviral (p  0.03) and
BV (p  0.002) endomyocardial infections were associ-
ted with decreased graft survival (Fig. 2F). The risk for
raft loss was 4.1 (95% CI: 1.13 to 14.73) times higher in
he adenovirus-positive patients and 8.5 (95% CI: 2.18 to
3.56) times higher in the EBV-positive patients compared
ith the PCR-negative patients. However, the predicted
raft survival for parvovirus endomyocardial infection was
imilar to that of PCR-negative patients. This was con-
ounded by the fact that the majority (17 of 23, 74%) of the
arvovirus-positive patients received IVIG therapy after a
CR-positive biopsy, which could have had a beneficial
ffect on the outcome. After adjusting for viral subtypes
sing Cox regression, EBV (p  0.03) and parvovirus (p 
.005) endomyocardial infections were associated with pre-
ature development of advanced TCAD. The risk for
dvanced TCAD was 7.5 (p 0.03, 95% CI: 1.76 to 45.07,
ox regression) times higher in the EBV-positive patients
nd 7.1 (p  0.005, 95% CI: 1.78 to 28.02, Cox regression)
imes higher in the parvovirus-positive patients compared
ContinuedTable 1 Continued
Characteristic
Donor age category, yrs
0–1
10–20
20–30
30–40
Donor CMV seropositivity
Recipient–donor mismatch variables
Sex mismatch
Ethnicity mismatch
Recipient–donor age ratio
Recipient–donor weight ratio
CMV mismatch: negative recipient, positive donor
HLA crossmatch positive
Post-transplantation course
Initial post-transplant hospital stay, days
Baseline immunosuppression
Cyclosporin
Tacrolimus
Azathioprine
Mycophenolate
Prednisone
Percentage of patients transitioned to 2-drug
regimen due to persistent leukopenia
Acute rejection episodes per patient-year
Number of rejection episodes in the first year after
transplantation
CMV viremia
EBV viremia
Values are n, n (%), or mean  SD unless otherwise indicated.
CHD  congenital heart disease; CMV  cytomegalovirus; DCM 
membrane oxygenation; HLA  human leukocyte antigen; ICU  inte
PCR  polymerase chain reaction; PCWP  pulmonary capillary wedg
resistance; RCM  restrictive cardiomyopathy; UNOS  United Netwoith the PCR-negative patients. No statistically significant wssociation was detected between AR and individual virus
ubtypes in our study cohort.
ffect of IVIG therapy on the outcome of patients with
CR-positive biopsies. Of the 37 patients with viral
CR-positive EMBs, 20 (54%) were treated with IVIG
ollowing a PCR-positive biopsy. The remaining 17 (46%)
ho did not receive IVIG therapy served as treatment-naive
ontrols. The mean time to IVIG treatment was 16.2 days
rom the PCR-positive biopsy (range 0 to 136 days). The
umber of IVIG doses that a patient received ranged from
to 3 doses (mean 1.6 doses, median 1 dose), with 7
atients receiving more than 1 IVIG dose due to multiple
CR-positive biopsies. The baseline characteristics of the
VIG-treated patients and IVIG-untreated controls are
iven in Table 2. Due to the surge in parvovirus-B19–
ositive EMBs in 2003 and 2004, the years during which
VIG therapy was administered for PCR-positive viral
ndomyocardial infection, the IVIG-treated PCR-positive
roup had a disproportionately higher number of
arvovirus-positive patients compared with the IVIG-
ntreated PCR-positive group. The other viral subtypes
-Positive Group PCR-Negative Group p Value
NS
4 (12.5%) 9 (19.6%)
16 (50.0%) 27 (58.7%)
11 (34.4%) 10 (21.7%)
1 (3.1%) 0 (0.0%)
25 (58.1%) 27 (56.3%) NS
17 (44.7%) 17 (43.6%) NS
21 (60.0%) 22 (64.7%) NS
1.0 0.49 1.3 1.18 NS
0.8 0.23 0.84 0.18 NS
14 (36.8%) 15 (35.7%) NS
4 (13.8%) 1 (3.1%) NS
8.1 30.44 27.2 66.93 NS
94.6% 90.9% NS
5.4% 9.1% NS
31.4% 41.2% NS
68.6% 55.8% NS
100% 100% NS
32.4% 46.4% NS
.52 0.83 0.58 1.09 NS
1.0 1.19 0.8 0.89 NS
54.1% 42.6% NS
62.6% 66.7% NS
cardiomyopathy; EBV  Epstein-Barr virus; ECMO  extracorporeal
are unit; LVAD  left ventricular assist device; NS  not significant;
ure; PSP  pulmonary systolic pressure; PVR  pulmonary vascular
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f transplant, was better in the IVIG-treated patients (p 
.05, log-rank) (Fig. 3C). The onset of advanced TCAD
fter becoming PCR positive was delayed in the IVIG-
reated patients compared with the untreated control group
p  0.03, log-rank) (Fig. 3D). The 3-year freedom from
dvanced TCAD after the first PCR-positive biopsy was
2% (95% CI: 24% to 97%) in the IVIG-treated patients
Baseline Characteristics of theIVIG-Treated and -Un reated Viral PCR-Positive PTable 2 B seline Charact ristics of theIVIG-Treated and -Untreated Viral PC
Characteristic
Patients
Recipient sex
Male
Female
Recipient ethnic group
White
Black
Hispanic
Asian
Recipient age, yrs
Recipient weight, kg
Indication for transplantation
CHD
CM
Retransplantation
Other
UNOS waiting-list status
1
2
Wait time, days (mean)
Donors
Donor cold ischemia time, min
Donor sex
Male
Female
Donor ethnicity
White
Black
Hispanic
Asian
Donor age, yrs
CMV mismatch: negative recipient, positive donor
Post-transplant viral endomyocardial infection
Viral subtypes
Adenovirus
EBV
Parvovirus B19
CMV
Enterovirus
Endomyocardial infection with 1 virus
Mean time to first PCR EMB after
transplantation, yrs
Values are n, n (%), or mean  SD unless otherwise indicated.
CM  cardiomyopathy; IVIG  intravenous immunoglobulin; other aompared with 45% (95% CI: 11% to 75%) in the IVIG- wntreated patients (p  0.03, log-rank). IVIG therapy did
ot affect the number of AR episodes after becoming PCR
ositive. In addition, it did not seem to help in the clearance
f viral genome. Viral genome was amplified from the
ollow-up biopsy in 48% of the IVIG-treated biopsies and
7% of the IVIG-untreated biopsies (p  NS, chi-square).
valid comparison of virus-free time after a PCR-positive
iopsy could not be performed as the follow-up biopsies
ts
sitive Patients
PCR-Positive
p Valuereated Group IVIG-Untreated Group
20 17
NS
9 (45%) 11 (65%)
1(55%) 6 (35%)
NS
7 (39%) 6 (38%)
2 (11%) 3 (19%)
8 (44%) 7 (43%)
1 (6%) 0 (0%)
1 6.01 9.8 5.19 NS
4 20.63 35.0 22.05 NS
NS
8 (40%) 3 (18%)
9 (45%) 7 (41%)
3 (15%) 5 (29%)
0 (0%) 2 (12%)
NS
3 (76%) 11 (65%)
4 (24%) 6 (35%)
157 153 NS
259 231 NS
NS
1 (73%) 9 (56%)
4 (27%) 7 (44%)
NS
8 (57%) 11 (73%)
2 (14%) 0 (0%)
4 (29%) 3 (20%)
0 (0%) 1 (0%)
5 6.79 11.3 6.93 NS
4 (21%) 7 (50%) NS
4 (20%) 5 (29%) NS
5 (25%) 3 (18%) NS
7 (85%) 6 (35%) 0.03
1 (5%) 3 (18%) NS
1 (5%) 0 (0%) NS
6 (30%) 2 (12%) NS
1.5 2.0 NS
tions as in Table 1.atien
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n this retrospective single-institution study, we show that
ccult viral endomyocardial infection (diagnosed by viral
CR-positive EMBs) after transplantation is common in
ediatric cardiac transplant patients and is associated with
remature graft loss. We also show that viral endomyocar-
ial infection is an independent risk factor for premature
oss of the cardiac allograft and appears to mediate this effect
hrough premature development of advanced TCAD. The
reatest risk for developing viral endomyocardial infection is
n the first year after transplantation (which is also the time
f maximal immunosuppression), parvovirus B19 infection
eing the most common, followed by adenovirus and EBV.
arvoviral B19 infection has a tendency for chronicity.
VIG therapy may improve graft survival and delay onset of
dvanced TCAD in the viral PCR-positive patients and
erits further evaluation.
tudy limitations. Our study is limited by its retrospective
Figure 3 Kaplan-Meier Analysis of the Utility of IVIG Therapy in
Pediatric Cardiac Transplant Patients With Viral Endo
(A) Overall graft survival tends to be worse in the PCR-positive intravenous immunoglo
negative patients. (B) Graft survival after developing viral endomyocardial infection ten
0.06, log-rank). (C) PCR-positive IVIG-untreated patients have an earlier overall onset
patients with viral endomyocardial infection delays the time to onset of advanced TCAature and low number of events, raising concerns for mnability to compensate for all baseline differences and
verfitting. The possibility that some of the patients classi-
ed as viral PCR-negative could have had undetected
ransient viral endomyocarditis may have resulted in an
nadvertent selection bias and inflated or deflated the true
trength of association between viral endomyocardial infec-
ion and an adverse outcome. However, these results repli-
ate our findings from a prior prospective trial performed in
completely different cohort of pediatric cardiac transplant
atients followed in a completely different institution and,
ence, are less likely to represent an alpha error (11). The
VIG therapy subgroup analysis is limited by an uncon-
rolled, retrospective analysis, small sample size, and un-
qual distribution of viral subtypes in the IVIG-treated and
untreated groups.
The prevalence of advanced TCAD was much higher in
ur patient cohort compared with recently published prev-
lence rates in pediatric heart transplant recipients in a
ardial Infection
IVIG)-untreated subgroup compared with PCR-positive IVIG-treated patients or PCR-
be better in the IVIG-treated patients compared with the IVIG-untreated controls (p 
nced TCAD compared with PCR-positive IVIG-treated patients. (D) IVIG therapy in
the first PCR-positive biopsy (p  0.03, log-rank). Abbreviations as in Figure 2.myoc
bulin (
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of adva
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ompared with a 6% 5-year probability in the Pahl et al.
tudy (25). This could be secondary to a difference in patient
emographics, immunosuppressive regimens, acute rejec-
ion episodes, incidence of viral endomyocarditis, or differ-
nces in case ascertainment, as coronary angiography inter-
retation is limited by subjectivity.
As indicated in Figure 2F, the presence of parvovirus does
ot appear to be associated with decreased graft survival
even though it was associated with higher risk for devel-
ping advanced TCAD). It is possible that since the
ajority of parvovirus infections were detected in the later
alf of the cohort, there may not have been enough time to
emonstrate an adverse effect on graft survival. In addition,
ince many of the parvovirus-positive patients were treated
ith IVIG, it is also possible that the graft survival curve has
een normalized due to the treatment. The number of
atients was too small to provide a significant comparison
etween the IVIG-treated and -untreated parvovirus
roups.
An association between the presence of adenovirus, en-
erovirus, or CMV genome in the myocardium and AR has
een previously described (8,10,11), but the lack of such an
ssociation in our study (which had a parvovirus predomi-
ance) leads us to speculate that unlike adenovirus, entero-
irus, and CMV, parvovirus does not result in AR, but may
till cause premature TCAD by chronic host-mediated
mmunologic response. The isolation of predominantly
arvovirus genome from cardiac allograft biopsies compared
ith adenovirus genome as previously reported by our group
11) leads us to speculate that similar to recent reports in
yocarditis patients (26), there has been an epidemiologic
hift in the predominant virus responsible for endomyocar-
ial infection after cardiac transplantation, from adenoviral
o a parvoviral predominance.
Therapeutic measures such as interferon beta therapy,
mmunoglobulins, or cellular immune therapy have been
ound to be beneficial in persistent viral myocarditis (27,28)
nd need to be explored in cardiac transplant patients who
evelop viral endomyocardial infection.
onclusions
e show that viral infection of the endomyocardium is
ommon in pediatric cardiac transplant recipients and is an
ndependent risk factor for graft loss. This effect on graft
oss seems to be mediated through premature development
f advanced TCAD. Our data suggest that an adverse
utcome may be delayed by using IVIG therapy. Hence,
erial PCR screening of surveillance endomyocardial biop-
ies for the presence of cardiotropic viruses is indicated in
ediatric cardiac transplant recipients. This will be crucial to
he development and evaluation of antiviral or other novel
herapeutic measures and potentially could improve long-
erm survival outcomes in these at-risk children.eprint requests and correspondence: Dr. Jeffrey A. Towbin,
he Heart Institute, Division of Pediatric Cardiology, Cincinnati
hildren’s Hospital Medical Center, 3333 Burnet Avenue, Cin-
innati, Ohio 45229. E-mail: jeffrey.towbin@cchmc.org.
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